Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Latest insights from the US healthcare market: Trends from leading healthcare conferences

Last week, the Bellevue Healthcare Funds and Mandates team attended the Wells Fargo Healthcare Conference in Boston, as well as the Citi BioPharma Back to School and Cantor Global Healthcare conferences in New York.
14.09.2026 - Stefan Blum, Guy Bettschart, Lorenzo Zignani, Markus Schweiger

Last week, the Bellevue Healthcare Funds and Mandates team attended the Wells Fargo Healthcare Conference in Boston, as well as the Citi BioPharma Back to School and Cantor Global Healthcare conferences in New York.

We are encouraged by attractive investment opportunities arising from innovation that delivers better outcomes for patients.

On the therapeutic side, recent developments in pulmonary hypertension are bringing patients new options. Roivant's success with mosliciguat will increase competitive pressure on United Therapeutics and Liquidia, while giving patients more choice and better tolerated medicines. In addition, the approval and launch of LISRAYA add a commercial component to Roivant's investment case.

We also see growing promise in combination treatments across immunological diseases, partly supported by the launch and development of safe, convenient oral alternatives, for example in psoriasis. J&J and Protagonist's oral IL-23 icotrokinra is seeing encouraging uptake. In parallel, AbbVie, Eli Lilly, Spyre and others are investigating numerous combination approaches across inflammatory conditions. For Protagonist, having discovered two approved products validates its peptide platform and gives the company greater capacity to fund its next wave of innovation.

Several medtech companies that have spent a long time out of favor are making a comeback. Medtronic appears to be overcoming its growth problems, not just in terms of sales but also earnings, supported by strong financial discipline. Becton Dickinson seems to be returning to its former strength after the sale of its Life Sciences division to Waters: stable growth of around 5% and strong cash flow generation, deployed mainly for share buybacks and dividends, should lift total returns toward 10%.

In US health insurance, companies confirmed that everything is on track, with the positive trend since the end of Q2 2026 continuing. In life sciences tools, the demand recovery in biopharma continues, and research demand should also pick up again next year.